Table 2.
Synthetic glucocorticoids in psychiatric disease associated with neural autoantibodies
| Number of patients | Type of neural autoantibody | Outcome of sGC monotherapy/polytherapy | References |
|---|---|---|---|
| Dementia | |||
| 57/145 | NMDAR, LGI1, CASPR2, AMPAR, GABAR, DPPX, GAD65, ARHGAP26, Ma1/2, Ri, Hu, Yo, AK5, BRSK2 | PT: 106/ 126 (84%) whole cohort unclear who many patients with dementia responded to PT | Endres et al. (2020) |
| 2/5 | IgANMDAR | PT: 1/2 (50%) | Doss et al. (2014) |
| 72 | Amphiphysin, GAD65, VGKC, AchR and CaCh, | PT: 46/72 (64%) | Flanagan et al. (2010) |
| LGI1 | Ariño et al. (2016) | ||
| 4/7 | IgANMDAR | PT: Improvement | Prüss et al. 2012 |
| 1 | IgLON5 | MT: sGC improvement | Hansen et al. (2020a) |
| 1 | Neurexin3alpha | MT: sGC no deterioration | Hansen et al. (2021b) |
| 1 | Flotilin 1/2 | MT: sGC improvement | Hansen et al. (2021a) |
| Psychosis | |||
| 20/72 |
Amphiphysin, GAD65, VGKC AchR and CaCh |
PT: 15/46 (33%) unclear who many patients with psychosis responded to PT | Flanagan et al. (2010) |
| 50/145 |
NMDAR, LGI1, CASPR2 AMPAR, GABAR, DPPX GAD65, ARHGAP26, Ma1/2, Ri, Hu, Yo, AK5, BRSK2 |
PT: 106/ 126 (84%) whole cohort unclear how many patients with psychosis responded to PT | Endres et al. (2020) |
| 7 | NMDAR | PT: Improvement | Prüss et al. (2012) |
| Catatonia | |||
| 1 | GABAAR | PT: Improvement | Samra et al. (2020) |
| Mood disorder | |||
| 16/145 |
NMDAR, LGI1, CASPR2 AMPAR, GABAR, DPPX GAD65, ARHGAP26, Ma1/2, Ri, Hu, Yo, AK5, BRSK2 |
PT: 106/ 126 (84%) whole cohort unclear how many patients with mood disorder responded to PT/ MT | Endres et al. (2020) |
| 20 | NMDAR | Restrepo-Martínez et al. (2020) | |
| 1 | IgM NMDAR | MT: Improvement | Choe et al. (2013) |
| 25/ 72 |
Amphiphysin, GAD65, VGKC AchR and CaCh |
PT: 15/46 (33%) unclear how many patients with mood disorder responded to PT | Flanagan et al. (2010) |
AcHR acetylcholine receptor, ARHGAP26 Rho GTPase-activating protein 26, BRSK2 brain selective Kinase 2, CaCh calcium channel, CASPR2 contactin-associated protein-like 2, GABAAR gamma aminobutyric acid A receptor, GAD65 glutamic acid decarboxylase 65, LGI1 leucine-rich glioma-inactivated protein 1, NMDAR N-methyl-d-aspartate receptor, PT polytherapy, VGKC voltage-gated potassium channel, MT monotherapy